| Name | Title | Contact Details |
|---|
Sentien Biotechnologies, Inc. is a privately owned, clinical stage company developing novel approaches to cell therapy. Our lead product is designed to allow for controlled, sustained delivery of mesenchymal stem cell (MSC) secreted factors. This approach immobilizes the MSCs in an extracorporeal device, allowing for doses of therapeutic secreted factors that are unattainable by direct injection.
Nurix Therapeutics discovers drugs that harness the body`s natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our focus is on developing drugs to treat cancer including novel, small molecule immuno-oncology agents.
Millennium, a leading biopharmaceutical company, applies its comprehensive and integrated science and technology platform for the discovery and development of breakthrough therapeutic and predictive medicine products, with a goal of delivering
Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases.
Delinia has assembled a leadership team, Board of Directors and Scientific Advisory Board comprised of experienced investors, world-class academicians and industry veterans with proven track records for building exceptional life sciences companies.